VITRAKVI is for adult and pediatric patients with NTRK gene fusion-positive solid tumors.

VITRAKVI is an oral medication that is not a chemotherapy.

  • VITRAKVI is the first medicine designed to block TRK fusion proteins
  • VITRAKVI is thought to work by blocking these proteins and stopping cancer cells from growing, but the exact way VITRAKVI works is unknown
  • VITRAKVI can work in a variety of tumor types as long as the tumor is caused by an NTRK gene fusion
Learn how VITRAKVI may help you

The #1 prescribed TRK* inhibitor for NTRK gene fusion-positive solid tumorsa


VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:

  • are caused by certain abnormal NTRK genes and
  • have spread or if surgery to remove their cancer is likely to cause severe complications, and
  • there is no acceptable treatment option or the cancer grew or spread on other treatment.

Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.

It is not known if VITRAKVI is safe and effective in children younger than 28 days of age.

VITRAKVI was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of VITRAKVI for this use.

*TRK, tropomyosin receptor kinase.

aBased on medical claims and prescription data claims for the period August 2019 through December 2020. Validated by IQVIA in March 2021.